Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：129頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2014’, provides an overview of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2014’, provides an overview of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview 9
Therapeutics Development 10
Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview 10
Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis 11
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Development by Companies 12
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Investigation by Universities/Institutes 15
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Development by Companies 19
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Investigation by Universities/Institutes 21
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development 22
AstraZeneca PLC 22
Athersys, Inc. 23
CardioVascular BioTherapeutics, Inc. 24
Sigma-Tau S.p.A. 25
Celgene Corporation 26
Cytokinetics, Incorporated 27
Cytomedix, Inc. 28
ReNeuron Group plc 29
Genovate Biotechnology Co., LTD. 30
Proteon Therapeutics, Inc. 31
Diffusion Pharmaceuticals LLC 32
Theravasc, Inc. 33
ViroMed Co., Ltd. 34
DNAVEC Corporation 35
miRagen Therapeutics, Inc. 36
RegenoCELL Therapeutics, Inc. 37
Provasculon, Inc. 38
Multi Gene Vascular Systems Ltd 39
Cardiolynx AG 40
Exodos Life Science Limited 41
Recardio GmbH 42
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Combination Products 44
Assessment by Target 45
Assessment by Mechanism of Action 48
Assessment by Route of Administration 51
Assessment by Molecule Type 53
Drug Profiles 55
ticagrelor - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
levocarnitine propionate hydrochloride - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ALD-301 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
tirasemtiv - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Trans Sodium Crocetinate - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
VM-202 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
sodium nitrite - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
sargramostim - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
SYN-20112312RU - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
cilostazol SR - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
MultiGeneAngio - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
filgrastim - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
DVC1-0101 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
CVBT-141C - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
PRT-201 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
REC-03 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
MultiGeneGraft - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
PDA-002 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
PF-05285401 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
ReN-009 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
MGN-6114 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Annexin A-5 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
AEM-28 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
ELS-140 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
PRV-0023 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
(organic nitrate + cilostazol) ER - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Autologous Stem Cell Therapy - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
PRV-0023 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Peripheral Vascular Disease Program - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Recent Pipeline Updates 95
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects 117
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products 119
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones 120
Featured News & Press Releases 120
Mar 05, 2013: Tarix Pharma's Peptide Technology Stimulates Revascularization Following Ischemia 120
Feb 28, 2013: Adventrx Pharma To Develop ANX-188 For Complications Of Arterial Disease 120
Dec 06, 2012: Cytomedix Announces Landmark Bright Cell Therapy Study In Peripheral Arterial Disease 121
Oct 15, 2012: Proteon Therapeutics Initiates Patient Enrollment In Phase I Clinical Study Of PRT-201 In Patients Suffering From Peripheral Artery Disease 122
Aug 23, 2012: Pluristem Commences Phase II Clinical Trial For Intermittent Claudication Using PLX Cells 122
Aug 17, 2012: Anges Announces Publication Of Long-Term Phase I/II Trial Data Of Collategene In Medical Journal 123
Jul 17, 2012: AstraZeneca To Initiate New Study Of BRILINTA In Patients With Peripheral Artery Disease 124
Jun 20, 2012: New Platelet Blocker Reduces Blood Clots And Artery-Opening Procedures, Study Finds 125
Jun 15, 2012: ReNeuron Presents Positive Preclinical Data Of ReN009 At 10th Annual Meeting Of International Society For Stem Cell Research 126
Feb 07, 2012: Merck Announces Top-Line Results Of TRA-2P Study Of Vorapaxar 126
Appendix 128
Methodology 128
Coverage 128
Secondary Research 128
Primary Research 128
Expert Panel Validation 128
Contact Us 129
Disclaimer 129
List of Tables
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2014 10
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Development by Companies, H1 2014 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Late Stage Development, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Development, H1 2014 18
Products under Development by Companies, H1 2014 19
Products under Development by Companies, H1 2014 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2014 21
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AstraZeneca PLC, H1 2014 22
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athersys, Inc., H1 2014 23
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2014 24
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Sigma-Tau S.p.A., H1 2014 25
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Celgene Corporation, H1 2014 26
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Cytokinetics, Incorporated, H1 2014 27
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Cytomedix, Inc., H1 2014 28
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ReNeuron Group plc, H1 2014 29
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Genovate Biotechnology Co., LTD., H1 2014 30
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Proteon Therapeutics, Inc., H1 2014 31
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Diffusion Pharmaceuticals LLC, H1 2014 32
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Theravasc, Inc., H1 2014 33
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ViroMed Co., Ltd., H1 2014 34
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by DNAVEC Corporation , H1 2014 35
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by miRagen Therapeutics, Inc., H1 2014 36
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by RegenoCELL Therapeutics, Inc., H1 2014 37
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Provasculon, Inc., H1 2014 38
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Multi Gene Vascular Systems Ltd, H1 2014 39
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Cardiolynx AG, H1 2014 40
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Exodos Life Science Limited, H1 2014 41
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Recardio GmbH, H1 2014 42
Assessment by Monotherapy Products, H1 2014 43
Assessment by Combination Products, H1 2014 44
Number of Products by Stage and Target, H1 2014 47
Number of Products by Stage and Mechanism of Action, H1 2014 50
Number of Products by Stage and Route of Administration, H1 2014 52
Number of Products by Stage and Molecule Type, H1 2014 54
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics - Recent Pipeline Updates, H1 2014 95
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H1 2014 117
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..1), H1 2014 118
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products, H1 2014 119
List of Figures
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2014 10
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Products, H1 2014 18
Assessment by Monotherapy Products, H1 2014 43
Number of Products by Top 10 Target, H1 2014 45
Number of Products by Stage and Top 10 Target, H1 2014 46
Number of Products by Top 10 Mechanism of Action, H1 2014 48
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 49
Number of Products by Top 10 Route of Administration, H1 2014 51
Number of Products by Stage and Top 10 Route of Administration, H1 2014 52
Number of Products by Top 10 Molecule Type, H1 2014 53
Number of Products by Stage and Top 10 Molecule Type, H1 2014 54
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview 9
Therapeutics Development 10
Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview 10
Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis 11
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Development by Companies 12
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Investigation by Universities/Institutes 15
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Development by Companies 19
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Investigation by Universities/Institutes 21
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development 22
AstraZeneca PLC 22
Athersys, Inc. 23
CardioVascular BioTherapeutics, Inc. 24
Sigma-Tau S.p.A. 25
Celgene Corporation 26
Cytokinetics, Incorporated 27
Cytomedix, Inc. 28
ReNeuron Group plc 29
Genovate Biotechnology Co., LTD. 30
Proteon Therapeutics, Inc. 31
Diffusion Pharmaceuticals LLC 32
Theravasc, Inc. 33
ViroMed Co., Ltd. 34
DNAVEC Corporation 35
miRagen Therapeutics, Inc. 36
RegenoCELL Therapeutics, Inc. 37
Provasculon, Inc. 38
Multi Gene Vascular Systems Ltd 39
Cardiolynx AG 40
Exodos Life Science Limited 41
Recardio GmbH 42
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Combination Products 44
Assessment by Target 45
Assessment by Mechanism of Action 48
Assessment by Route of Administration 51
Assessment by Molecule Type 53
Drug Profiles 55
ticagrelor - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
levocarnitine propionate hydrochloride - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ALD-301 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
tirasemtiv - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Trans Sodium Crocetinate - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
VM-202 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
sodium nitrite - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
sargramostim - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
SYN-20112312RU - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
cilostazol SR - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
MultiGeneAngio - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
filgrastim - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
DVC1-0101 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
CVBT-141C - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
PRT-201 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
REC-03 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
MultiGeneGraft - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
PDA-002 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
PF-05285401 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
ReN-009 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
MGN-6114 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Annexin A-5 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
AEM-28 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
ELS-140 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
PRV-0023 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
(organic nitrate + cilostazol) ER - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Autologous Stem Cell Therapy - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
PRV-0023 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Peripheral Vascular Disease Program - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Recent Pipeline Updates 95
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects 117
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products 119
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones 120
Featured News & Press Releases 120
Mar 05, 2013: Tarix Pharma's Peptide Technology Stimulates Revascularization Following Ischemia 120
Feb 28, 2013: Adventrx Pharma To Develop ANX-188 For Complications Of Arterial Disease 120
Dec 06, 2012: Cytomedix Announces Landmark Bright Cell Therapy Study In Peripheral Arterial Disease 121
Oct 15, 2012: Proteon Therapeutics Initiates Patient Enrollment In Phase I Clinical Study Of PRT-201 In Patients Suffering From Peripheral Artery Disease 122
Aug 23, 2012: Pluristem Commences Phase II Clinical Trial For Intermittent Claudication Using PLX Cells 122
Aug 17, 2012: Anges Announces Publication Of Long-Term Phase I/II Trial Data Of Collategene In Medical Journal 123
Jul 17, 2012: AstraZeneca To Initiate New Study Of BRILINTA In Patients With Peripheral Artery Disease 124
Jun 20, 2012: New Platelet Blocker Reduces Blood Clots And Artery-Opening Procedures, Study Finds 125
Jun 15, 2012: ReNeuron Presents Positive Preclinical Data Of ReN009 At 10th Annual Meeting Of International Society For Stem Cell Research 126
Feb 07, 2012: Merck Announces Top-Line Results Of TRA-2P Study Of Vorapaxar 126
Appendix 128
Methodology 128
Coverage 128
Secondary Research 128
Primary Research 128
Expert Panel Validation 128
Contact Us 129
Disclaimer 129
List of Tables
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2014 10
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Development by Companies, H1 2014 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Late Stage Development, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Development, H1 2014 18
Products under Development by Companies, H1 2014 19
Products under Development by Companies, H1 2014 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2014 21
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AstraZeneca PLC, H1 2014 22
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athersys, Inc., H1 2014 23
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2014 24
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Sigma-Tau S.p.A., H1 2014 25
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Celgene Corporation, H1 2014 26
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Cytokinetics, Incorporated, H1 2014 27
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Cytomedix, Inc., H1 2014 28
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ReNeuron Group plc, H1 2014 29
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Genovate Biotechnology Co., LTD., H1 2014 30
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Proteon Therapeutics, Inc., H1 2014 31
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Diffusion Pharmaceuticals LLC, H1 2014 32
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Theravasc, Inc., H1 2014 33
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ViroMed Co., Ltd., H1 2014 34
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by DNAVEC Corporation , H1 2014 35
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by miRagen Therapeutics, Inc., H1 2014 36
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by RegenoCELL Therapeutics, Inc., H1 2014 37
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Provasculon, Inc., H1 2014 38
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Multi Gene Vascular Systems Ltd, H1 2014 39
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Cardiolynx AG, H1 2014 40
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Exodos Life Science Limited, H1 2014 41
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Recardio GmbH, H1 2014 42
Assessment by Monotherapy Products, H1 2014 43
Assessment by Combination Products, H1 2014 44
Number of Products by Stage and Target, H1 2014 47
Number of Products by Stage and Mechanism of Action, H1 2014 50
Number of Products by Stage and Route of Administration, H1 2014 52
Number of Products by Stage and Molecule Type, H1 2014 54
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics - Recent Pipeline Updates, H1 2014 95
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H1 2014 117
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..1), H1 2014 118
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products, H1 2014 119
List of Figures
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2014 10
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Products, H1 2014 18
Assessment by Monotherapy Products, H1 2014 43
Number of Products by Top 10 Target, H1 2014 45
Number of Products by Stage and Top 10 Target, H1 2014 46
Number of Products by Top 10 Mechanism of Action, H1 2014 48
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 49
Number of Products by Top 10 Route of Administration, H1 2014 51
Number of Products by Stage and Top 10 Route of Administration, H1 2014 52
Number of Products by Top 10 Molecule Type, H1 2014 53
Number of Products by Stage and Top 10 Molecule Type, H1 2014 54
